Table 6 includes drugs with clinically important drug interactions when administered concomitantly with XELJANZ/XELJANZ XR/XELJANZ Oral Solution and instructions for preventing or managing them.
Strong CP3A4 Inhibitors (e.g., ketoconazole) | |
Clinical Impact | Increased exposure to tofacitinib |
Intervention | Dosage adjustment of XELJANZ/XELJANZ XR/XELJANZ Oral Solution is recommended |
Moderate CYP3A4 Inhibitors Coadministered with Strong CYP2C19 Inhibitors (e.g., fluconazole) | |
Clinical Impact | Increased exposure to tofacitinib |
Intervention | Dosage adjustment of XELJANZ/XELJANZ XR/XELJANZ Oral Solution is recommended |
Strong CYP3A4 Inducers (e.g., rifampin) | |
Clinical Impact | Decreased exposure to tofacitinib and may result in loss of or reduced clinical response |
Intervention | Coadministration with XELJANZ/XELJANZ XR/XELJANZ Oral Solution is not recommended |
Immunosuppressive Drugs (e.g., azathioprine, tacrolimus, cyclosporine) | |
Clinical Impact | Risk of added immunosuppression; coadministration with biologic DMARDs or potent immunosuppressants has not been studied in patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, UC, or pcJIA. |
Intervention | Coadministration with XELJANZ/XELJANZ XR/XELJANZ Oral Solution is not recommended |
Table 6 includes drugs with clinically important drug interactions when administered concomitantly with XELJANZ/XELJANZ XR/XELJANZ Oral Solution and instructions for preventing or managing them.
Strong CP3A4 Inhibitors (e.g., ketoconazole) | |
Clinical Impact | Increased exposure to tofacitinib |
Intervention | Dosage adjustment of XELJANZ/XELJANZ XR/XELJANZ Oral Solution is recommended |
Moderate CYP3A4 Inhibitors Coadministered with Strong CYP2C19 Inhibitors (e.g., fluconazole) | |
Clinical Impact | Increased exposure to tofacitinib |
Intervention | Dosage adjustment of XELJANZ/XELJANZ XR/XELJANZ Oral Solution is recommended |
Strong CYP3A4 Inducers (e.g., rifampin) | |
Clinical Impact | Decreased exposure to tofacitinib and may result in loss of or reduced clinical response |
Intervention | Coadministration with XELJANZ/XELJANZ XR/XELJANZ Oral Solution is not recommended |
Immunosuppressive Drugs (e.g., azathioprine, tacrolimus, cyclosporine) | |
Clinical Impact | Risk of added immunosuppression; coadministration with biologic DMARDs or potent immunosuppressants has not been studied in patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, UC, or pcJIA. |
Intervention | Coadministration with XELJANZ/XELJANZ XR/XELJANZ Oral Solution is not recommended |
{{section_body_html_patient}}
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
Pfizer Safety
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
FDA Medwatch
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.